Research and development plays an important role within the Carl Zeiss Meditec Group. Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products.
Carl Zeiss Meditec Group has the necessary resources to secure the Company’s future earnings strength with its research and development activities. Thus we also want to offer innovations in future that make leading technologies available for our customers, and thus improve treatment results for patients.
Research and development at the Company mainly focuses on:
The long and successful history is marked with numerous milestones and innovations that have enabled the company to drive the progress of medical technology. Several of these products, and how the latest developments shape the future, are presented on the following pages.
The first digital microscope in ophthalmic surgery comes with a new feature called “DigitalOptics” which provides unmatched depth of field, drastically reduced light intensity requirements and real color impression for increased certainty. It also provides digital assistance and detailed information to surgical vision in real-time.
This visualization system expands the range of clinical applications for spine surgeons and gives the field of spine surgery access to cutting-edge technologies.
The next generation of photocoagulation laser from ZEISS allows doctors to fully concentrate on the patient’s treatment procedure without interruption.
The first Robotic Visualization System sets a new benchmark in assisting surgeons with additional insights for better clinical decisions, while reducing complexity and manual repositioning.
Fundus imaging system provides practitioners a better view of the entire fundus with exceptional images closely resembling the coloration of the retina, down to 7 microns in an ultra-widefield view from the macula to the far periphery.
With the Extended Depth of Focus (EDoF), giving surgeons a new option for astigmatic patients with an active lifestyle and a need for spectacle independence in distance and intermediate vision.
It is poised to revolutionize and differentiate dental practices with Augmented Visualization, Digital Patient Communication and Single-Handed Operation.
The AngioPlex™ OCT Angiography technology helps doctors to display retinal blood vessels without the need for the injection of fluorescent liquids into the patient's eye. Vascular changes in the retina and choroid can now be examined non-invasively and displayed in three dimensions using optical coherence tomography.
ZEISS offers an extensive range of hydrophilic intraocular lenses and with the launch of the hydrophobic monofocal intraocular lens CT LUCIA® one of the most comprehensive IOL portfolios on the market.
The IOLMaster® 700 with SWEPT Source Biometry™ enables physicians to identify irregular geometries of the eye in their patients at an early stage. In addition to optical biometry, it also offers OCT9 imaging across the entire length of the eye. Experts say that this produces more reliable refractive results.
This system for integrated intraoperative OCT imaging combines two of the Company’s gold standard technologies. The system incorporates the OPMI LUMERA® 700 surgical microscope with the integrated OCT camera RESCAN™ 700. The system provides surgeons with top-quality OCT images of the eye, intraoperatively.
AT LISA® and AT LISA® tri are part of the a new generation of high-performance multifocal IOLs.
Also on its way to becoming a new standard: the VisuMax® femtosecond laser. Surgeons have been successfully using this system since 2006.
INTRABEAM® is an innovative system for breast cancer and is tested in numerous clinical studies.
Today, selecting the right IOL to meet individual patient expectations is more crucial than ever. The IOLMaster® incorporates advancements designed with the challenges of today’s cataract practice in mind.
Introduced in 1997, optical coherence tomography (OCT) from assists doctors in the examination of patients with serious diseases of the retina.
Since 1984, the HFA has been the accepted standard of care in glaucoma diagnosis and management, validated by many years of research design and clinical experience.
The Photocoagulator is designed to provide eye doctors of various disciplines and backgrounds optimum flexibility for a broad spectrum of retinal therapies.
The first prototypes of the first surgical microscope, the ZEISS OPMI® 1, were developed in the early the 1950s under the guidance of physicist Hans Littmann.
ZEISS developed the first slit lamp together with Swedish doctor Allvar Gullstrand. This development laid the foundation for medical technology at Carl Zeiss.